Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 4—April 2008

Research

Seroprevalence and Risk Factors for Human Herpesvirus 8 Infection, Rural Egypt1

Sam M. Mbulaiteye*Comments to Author , Ruth M. Pfeiffer*, Bryan Dolan*, Victor C.W. Tsang†, John Noh†, Nabiel N.H. Mikhail‡, Mohamed Abdel-Hamid§¶, Mohamed Hashem§¶, Denise Whitby#, G. Thomas Strickland¶, and James J. Goedert*
Author affiliations: *National Cancer Institute, Bethesda, Maryland, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ‡Assiut University, Cairo, Egypt; §National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; ¶University of Maryland School of Medicine, Baltimore, Maryland, USA; #National Cancer Institute-Frederick, Frederick, MD, USA;

Main Article

Table 3

Adjusted OR of association of HHV-8 seropositivity with demographic and clinical variables among adults, Egypt*

Characteristic Men
Women
OR 95% CI p value OR 95% CI p value
Age group, y† 0.002
15–24 Ref Ref
25–34 1.6 1.2–2.2 0.8 0.4–1.6 0.53
35–44 2.6 1.4–4.9 1.5 0.8–2.9 0.15
>45
4.3
1.7–11.0


3.1
1.5–6.4
<0.001
Dental treatments‡ 0.04
No Ref
Yes
2.3
1.1–4.9





HCV serostatus‡ 0.007
Negative Ref
Positive




3.3
1.4–7.9

Schistosomiasis§ 0.47 0.07
Negative Ref Ref
Positive 2.3 0.3–16.1 1.5 1.0–2.5

*OR, odds ratio; HHV-8, human herpesvirus 8; CI, confidence interval; Ref, referrent; HCV, hepatitis C virus.
†p value is for age group fitted with trend among men; p values for heterogeneity for categories given for women (see Statistical Methods).
‡Missing values in sex-specific analyses mean the variable was not significant and was excluded from final multivariable model.
§Schistosomiasis seropositivity was included in models even when not significant because we hypothesized a priori that it was associated with HHV-8 seropositivity (see online Appendix, available from www.cdc.gov/EID/content/14/4/586-app.htm).

Main Article

1Results were presented, in part, at the 9th International Workshop on Kaposi’s Sarcoma–associated Herpesvirus (KSHV) and Related Agents, Cape Cod, Massachusetts, USA, July 12–15, 2006.

TOP